- Home
- AUUD vs GRI Comparison
AUUD vs GRI Comparison
Compare AUUD & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- GRI
- Stock Information
- Founded
- AUUD 2012
- GRI 2018
- Country
- AUUD United States
- GRI United States
- Employees
- AUUD N/A
- GRI N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- GRI Health Care
- Exchange
- AUUD Nasdaq
- GRI Nasdaq
- Market Cap
- AUUD 3.1M
- GRI 3.0M
- IPO Year
- AUUD 2021
- GRI N/A
- Fundamental
- Price
- AUUD $0.51
- GRI $0.77
- Analyst Decision
- AUUD
- GRI Strong Buy
- Analyst Count
- AUUD 0
- GRI 1
- Target Price
- AUUD N/A
- GRI $12.00
- AVG Volume (30 Days)
- AUUD 115.3K
- GRI 9.9M
- Earning Date
- AUUD 11-07-2024
- GRI 11-14-2024
- Dividend Yield
- AUUD N/A
- GRI N/A
- EPS Growth
- AUUD N/A
- GRI N/A
- EPS
- AUUD N/A
- GRI N/A
- Revenue
- AUUD N/A
- GRI N/A
- Revenue This Year
- AUUD N/A
- GRI N/A
- Revenue Next Year
- AUUD N/A
- GRI N/A
- P/E Ratio
- AUUD N/A
- GRI N/A
- Revenue Growth
- AUUD N/A
- GRI N/A
- 52 Week Low
- AUUD $0.48
- GRI $0.30
- 52 Week High
- AUUD $11.75
- GRI $106.29
- Technical
- Relative Strength Index (RSI)
- AUUD 35.17
- GRI 49.32
- Support Level
- AUUD $0.53
- GRI $0.79
- Resistance Level
- AUUD $0.61
- GRI $1.00
- Average True Range (ATR)
- AUUD 0.05
- GRI 0.17
- MACD
- AUUD -0.00
- GRI -0.02
- Stochastic Oscillator
- AUUD 16.06
- GRI 24.95
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products include Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.